Posted by Michael Wonder on 02 Sep 2020
NICE unable to assess new indication for Soliris
2 September 2020 - NICE was hopeful of being able to assess eculizumab for the treatment of patients with relapsing neuromyelitis optica.
NICE is unable to make a recommendation about the use in the NHS of eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK did not provide an evidence submission.
NICE will review this decision if Alexion Pharma UK decides to make a submission.
